Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
出版年份 2022 全文链接
标题
Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2022-10-07
DOI
10.1111/bjh.18479
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma
- (2022) Jithma P. Abeykoon et al. BRITISH JOURNAL OF HAEMATOLOGY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
- (2021) Saad Z Usmani et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
- (2021) Yael C. Cohen et al. BLOOD
- Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma
- (2021) Tahani Atieh et al. BLOOD
- “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
- (2021) I. Vaxman et al. Blood Cancer Journal
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma
- (2019) Ajai Chari et al. Clinical Lymphoma Myeloma & Leukemia
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support
- (2008) Paul A. Harris et al. JOURNAL OF BIOMEDICAL INFORMATICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started